Request Demo
Recent blog posts
Industry Reports
2 min read
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(1)
29 August 2024
Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Industry Reports
2 min read
May 2023 Global Innovative Drug Report
7 July 2023
The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.
Industry Reports
2 min read
April 2023 Global Innovative Drug Report
30 June 2023
The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.
Industry Reports
2 min read
March 2023 Global Innovative Drug Report
28 June 2023
The report offers a comprehensive overview of the latest advancements in the pharmaceutical industry.